Executive Summary
Envalith conducted an interview with Mr. Fujimoto (Director and Chief Financial Officer) regarding J-Pharma Co.,Ltd.'s decision to expand Part A of the international Phase 3 trial "Beacon-BTC" for nanvuranlat into Japan and South Korea. The company announced plans to add Japan and South Korea to Part A of Beacon-BTC, its global Phase 3 trial in biliary tract cancer. The original design called for Part A to be conducted in the US alone, with global expansion beginning in Part B. Selection for AMED's GRiT program prompted a strategic shift to simultaneously strengthen development funding, patient enrollment, and geographic reach. By launching early in Japan and Korea, the company aims to reduce execution risk at the transition to Part B and to build the business foundation for future regulatory filings and partnering negotiations ahead of schedule. Beyond the non-dilutive grant of up to JPY 1.5B, AMED's validation of the trial design and operational framework represents an important signal for investors.
Message from the Company
AMED's experts judged both the content of the clinical trial and our operational framework to be worthy of a grant. We would like investors to appreciate this point indirectly as well.
Key Discussion Points
Japan/Korea Addition Enhances the Strategic Value of Beacon-BTC
The company will incorporate Japan and South Korea into Part A, which was originally planned for the US only. The move follows selection for AMED's GRiT program, which supports international joint clinical trials including Japan in rare disease indications. The rationale extends well beyond grant funding to include lower enrollment risk, deeper engagement with specialist physicians, and earlier dialogue with regulators. In Korea, the company is also mindful of potential partners; early inclusion in the trial is intended to enhance commercialization options in that market.
Front-Loaded Investment Aimed at a Smooth Transition to Part B
Total enrollment in Part A remains unchanged at approximately 120 patients, with a portion of US cases reallocated to Japan and Korea. US site activation and patient enrollment are progressing as planned, and management indicates the trial could be completed with US sites alone. The reason for including Japan and Korea from Part A is to have trial infrastructure in both countries ready at the start of Part B, enabling globally balanced patient enrollment. Because the subtype mix in biliary tract cancer differs between the US and East Asia, adding Japanese and Korean data should bring the dataset closer to the global patient distribution.
Nanvuranlat Positioned in a Treatment Gap With No Approved Therapies
Beacon-BTC is designed for biliary tract cancer patients moving from first-line to second-line therapy. In the US and Europe, roughly 30% of second-line patients have molecular targeted therapy options, while the remaining ~70% have no approved treatment. For this untreated segment, the company is pursuing approval by comparing nanvuranlat against treatment options used in real-world clinical practice in an area of substantial unmet medical need. In Japan, the treatment landscape differs as TS-1 is approved for biliary tract cancer. Nevertheless, if nanvuranlat establishes itself as a global second-line agent, the company expects broad use in the Japanese market as well.
Envalith's Perspectives
AMED's GRiT program subsidizes one-half of eligible costs incurred after project commencement, with support of up to JPY 1.5B anticipated. Beyond the non-dilutive nature of the grant, it is significant that AMED evaluated the trial content and operational framework including non-public information. For a biotech venture, third-party expert validation helps mitigate investor uncertainty.
Total Part A enrollment remains at approximately 120 patients; adding Japan and Korea does not materially increase overall trial size. Rather, by front-loading regulatory engagement, site contracting, and specialist physician relationships, the company aims to smooth the launch of Part B, the confirmatory phase. We view this as a management decision to pre-empt the regional start-up delays that typically emerge in later-stage development.
Japan, Korea, China, and certain other territories are covered under the agreement with Ohara Pharmaceutical, while J-Pharma Co.,Ltd. retains rights for the US and Europe. If Part A demonstrates a meaningful efficacy signal primarily in US patients, the company intends to explore US/European licensing deals after enhancing the compound's value. The model assumes regional partners rather than in-house commercialization, reflecting a focus on capital efficiency in the event of development success.
Regulatory engagement and institutional contracting in Japan and Korea may take longer than anticipated; the final terms of the AMED grant remain undetermined; Part A may fail to produce sufficient efficacy and safety signals; and the timing and terms of partnering negotiations are subject to market conditions.
Q&A Highlights
- Q
What is the primary objective of adding Japan and South Korea to Part A?
AMeeting AMED GRiT program requirements enables access to a grant of up to JPY 1.5B, but the company's objective is not purely financial. The core aims are strengthening collaboration with specialist physicians in Japan and Korea, initiating regulatory dialogue, and building the infrastructure to facilitate the future transition to Part B. In Korea, enhanced appeal to potential partners is also a consideration.
- Q
Will the Japan/Korea addition change the size or timeline of Part A?
ATotal Part A enrollment of approximately 120 patients remains unchanged. A portion of the cases originally planned for the US will be reallocated to Japan and Korea; overall scale will not expand. US site activation and enrollment are on track, and the company is advancing regulatory consultations and site start-up to avoid any delay from the Japan/Korea addition.
- Q
What is the clinical rationale for including East Asia?
AThe subtype mix in biliary tract cancer differs between the US and East Asia. Including these regions should bring the proportions of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer closer to the global distribution than a US-only trial. Understanding regional differences early will also inform trial design and filing strategy from Part B onward.
- Q
Which patient population does nanvuranlat target?
ABeacon-BTC targets previously treated advanced biliary tract cancer, specifically intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer, enrolling patients who meet defined eligibility criteria including prior treatment history and performance status. In the US and Europe, roughly 30% of second-line patients are eligible for molecular targeted therapy, while the remaining ~70% have no approved option. The company is targeting approval in this large unmet-need segment by comparing nanvuranlat against treatment options used in real-world clinical practice.
- Q
What commercialization model is envisaged post-approval?
AUnder the existing agreement, Ohara Pharmaceutical handles development and commercialization in Japan, Korea, China and certain other Asian territories as well as Africa. J-Pharma Co.,Ltd. retains the US and European rights, and if Part A demonstrates meaningful efficacy in a population including US patients, the company could enhance the compound's value and then pursue a licensing agreement. There is currently no intention for the company to act as a marketing authorization holder itself; the model relies on partners in each country and region.
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.